First Results From Editas CRISPR Eye Therapy Underwhelm Investors
Safety Is Reassuring But Efficacy Unclear
While rivals Intellia impressed with their first in vivo CRISPR gene-editing data, Editas’s first results in just two patients are not enough to convince investors.
You may also be interested in...
The French biotech has managed to bag a blue-chip partner to advance its ambitions to be the leading company in the ocular genomic medicine space, getting access to Intellia's CRISPR/Cas9 technology.
The first use of CRISPR/Cas9 in humans shows promising safety and efficacy against rare disease ATTR, and opens up the possibility of treating many genetic diseases.
The Dutch biotech has firmed up its finances as its promising pipeline of RNA therapies for rare genetic eye disease starts to move through the clinic.